Dr. Esselen is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
Beth Israel Deaconess Hospital
330 Brookline Ave
Boston, MA 02215Phone+1 617-667-4040
Summary
- Dr. Katharine Esselen is an experienced Obstetrics and Gynecology specialist based in Boston, MA, with a specific focus on Gynecologic Oncology. She completed her fellowship and residency in Obstetrics and Gynecology at Brigham and Women’s Hospital and is currently an instructor at Harvard Medical School at Beth Israel Deaconess Medical Center. She possesses extensive knowledge and expertise in hereditary breast/ovarian cancer, uterine carcinoma, endometrial carcinoma, fallopian tube carcinoma, and hysterectomy. Additionally, she has made notable contributions to her field, as evidenced by her various publications relating to gynecologic cancers and the financial toxicity of treatment.
Education & Training
- Brigham and Women’s HospitalFellowship, Gynecologic Oncology, 2012 - 2015
- Brigham and Women's Hospital/Massachusetts General Hospital/Harvard Medical SchoolResidency, Obstetrics and Gynecology, 2008 - 2012
- Tufts University School of MedicineClass of 2008
Certifications & Licensure
- MA State Medical License 2012 - 2025
- American Board of Obstetrics and Gynecology Obstetrics & Gynecology
- American Board of Obstetrics and Gynecology Gynecologic Oncology
Publications & Presentations
PubMed
- 23 citationsCrowdsourcing to measure financial toxicity in gynecologic oncology.Katharine M. Esselen, Hannah Stack-Dunnbier, Annika Gompers, Michele R. Hacker
Gynecologic Oncology. 2021-02-05 - 78 citationsFinancial toxicity in gynecologic oncologySara Bouberhan, Meghan Shea, Alice Kennedy, Adrienne L. Erlinger, Hannah Stack-Dunnbier
Gynecologic Oncology. 2019-07-01 - 23 citationsGermline mutations of SMARCA4 in small cell carcinoma of the ovary, hypercalcemic type and in SMARCA4-deficient undifferentiated uterine sarcoma: Clinical features of ...Yamicia D. Connor, Diana Miao, Douglas I. Lin, Cynthia Hayne, Brooke E. Howitt
Gynecologic Oncology. 2020-01-15
Press Mentions
- Financial Toxicity Impacts Nearly 50% of Women with Gynaecologic CancerJune 15th, 2021
- Financial Toxicity Associated with Cancer Care Impacts Nearly 50% of Women with Gynecologic Cancer and Disproportionately AffectsJune 11th, 2021
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: